LDL-C / ApoB

The LDL-C to ApoB ratio is an advanced cardiovascular biomarker that helps you understand not just how much cholesterol is circulating in your blood, but what type of LDL particles are carrying it. It’s calculated by dividing your LDL cholesterol (LDL-C) level by your apolipoprotein B (ApoB) level.

Every LDL particle contains exactly one ApoB molecule — so while LDL-C measures the cholesterol content inside the particles, ApoB counts the particles themselves. Comparing the two gives clinicians a powerful proxy for LDL particle size and density — key determinants of heart disease risk that traditional cholesterol tests can miss.

In simple terms:
It helps distinguish cholesterol content from particle number.

• LDL-C = the total amount of cholesterol inside LDL particles

• ApoB = the number of LDL (and other atherogenic) particles, because each particle carries one ApoB protein

Why the ratio matters:

Two people can have the same LDL-C but very different ApoB levels. This ratio helps identify whether LDL particles are:

• Cholesterol-rich and fewer in number, or

• Cholesterol-poor but numerous (often smaller, denser particles)

Not all LDL is created equal. Smaller, denser LDL particles are more likely to penetrate arterial walls, become oxidized, and trigger inflammation — processes that accelerate atherosclerosis. A lower LDL-C/ApoB ratio suggests a higher number of these small, dense, atherogenic particles, even if your total LDL cholesterol looks “normal.” Conversely, a higher ratio means your LDL particles are larger and carry more cholesterol each — typically less harmful to arteries.

Multiple large-scale studies have shown that this ratio can predict major cardiovascular events (MACE) — including heart attack, stroke, and cardiovascular death — independently of total LDL levels. In other words, two people could have the same LDL-C, but very different risks depending on how their cholesterol is packaged.

This marker also predicts cardiovascular and all-cause mortality in the general population. Lower ratios have been associated with increased mortality risk, particularly in older adults, highlighting its potential as a long-term prognostic marker.

Who It's Most Useful For

The LDL-C/ApoB ratio offers value across a wide range of patients, but it’s especially insightful in certain groups. In people with type 2 diabetes, a low ratio strongly predicts coronary heart disease, even when traditional scores like ASCVD underestimate the risk. It’s also a helpful tool in non-diabetic individuals who don’t have high LDL-C levels but may still harbor a large number of small, dense LDL particles—a subtle but important red flag for early atherosclerosis.

By refining cardiovascular risk assessment, the LDL-C/ApoB ratio helps clinicians tailor prevention and treatment strategies — identifying those who might benefit from more aggressive lipid-lowering therapies or lifestyle interventions despite having “normal” cholesterol numbers.

If your LDL-C/ApoB ratio is low (indicating small, dense LDL particles), focus on strategies that improve LDL particle quality and reduce overall cardiovascular risk.

• Diet: Emphasise whole, unprocessed foods; reduce refined carbohydrates and added sugars; and include healthy fats such as olive oil, nuts, avocado, and fatty fish.

• Exercise: Regular aerobic and resistance training can improve lipid particle size and insulin sensitivity.

• Lifestyle: Prioritise sleep, manage stress, and avoid smoking—all of which impact lipid metabolism.

• Medical care: Discuss results with your clinician; you may benefit from further lipid testing or therapeutic adjustments to statins, PCSK9 inhibitors, or other lipid-modifying agents.
  

Over time, lifestyle and treatment decisions aimed at improving metabolic health — particularly reducing insulin resistance and chronic inflammation — can help shift LDL particles from small and dense to larger and more buoyant, thereby improving this ratio.

1. Drexel, H., Larcher, B., Mader, A., et al. (2021). The LDL-C/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease. Atherosclerosis, 329, 44–49. https://doi.org/10.1016/j.atherosclerosis.2021.05.010
   

2. Xiao, L., Zhang, K., Wang, F., et al. (2023). The LDL-C/ApoB ratio predicts cardiovascular and all-cause mortality in the general population. Lipids in Health and Disease, 22(1), 104. https://doi.org/10.1186/s12944-023-01869-1
   

3. Rabizadeh, S., Rajab, A., Mechanick, J. I., et al. (2021). LDL/ApoB ratio predicts coronary heart disease in type 2 diabetes independent of ASCVD risk score: A case-cohort study. Nutrition, Metabolism & Cardiovascular Diseases, 31(5), 1477–1485. https://doi.org/10.1016/j.numecd.2021.01.013
   

4. Jung, H. W., Ra, M., Bae, H. J., & Hong, S. P. (2023). The LDL-C/ApoB ratio predicts coronary atherosclerotic heart disease in non-diabetic patients without high LDL-C. Medicine, 102(1), e32596. https://doi.org/10.1097/MD.0000000000032596